Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current...
Main Authors: | Pecenak J, Novotny V |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-11-01
|
Series: | Neuropsychiatric Disease and Treatment |
Online Access: | http://www.dovepress.com/corrigendum-agomelatine-as-monotherapy-for-major-depression-an-ou-a15090 |
Similar Items
-
Agomelatine as monotherapy for major depression: an outpatient, open-label study
by: Pecenak J, et al.
Published: (2013-10-01) -
Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study
by: Fornaro M, et al.
Published: (2013-02-01) -
Agomelatine for postpartum depression and breastfeeding
by: Le Xiao
Published: (2021-06-01) -
A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder
by: Ravi Babu. Komaram, et al.
Published: (2015-06-01) -
Efficacy and tolerability of agomelatine in the treatment of depression
by: Plesničar BK
Published: (2014-05-01)